Puma Biotechnology (PBYI) FCF Margin (2017 - 2026)

Puma Biotechnology's FCF Margin history runs 10 years deep, the most recent figure standing at 34.4% for Q1 2026.

• Quarterly FCF Margin rose 2668.0% year-over-year to 34.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23.59% (up 1020.0% YoY) and the FY2025 annual result came in at 18.27%, up 141.0% from the prior year.
• FCF Margin was 34.4% for Q1 2026 at Puma Biotechnology, up from 19.16% in the prior quarter.
• Across five years, FCF Margin topped out at 34.4% in Q1 2026 and bottomed at 58.8% in Q1 2022.
• A 5-year average of 10.3% and a median of 14.45% in 2023 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin sank 7476 bps — and 2023, when it surged 6381 bps.
• Puma Biotechnology's FCF Margin stood at 8.77% in 2022, then jumped by 65 bps to 14.45% in 2023, then soared by 82 bps to 26.36% in 2024, then retreated by 27 bps to 19.16% in 2025, then jumped by 80 bps to 34.4% in 2026.
• Business Quant data shows PBYI's FCF Margin at 34.4% in Q1 2026, 19.16% in Q4 2025, and 17.61% in Q3 2025.